Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Preoperative Serum Biomarkers Improve Prediction of Poor Postoperative Outcome After Cardiopulmonary Bypass Compared With Clinical Variables in Neonates.

Created on 18 Nov 2026

Authors

Monique M Gardner, Daniel Balcarcel, Fang Chen, Andrew Huff, Robert Olsen, Kyle Winser, Andrea Kennedy, Hillary R Bogner, Rui Feng, Anh D Mai, Vanessa Gonzalez, Joseph Fraietta, Asif Padiyath, Scott L Weiss, J William Gaynor, Nadir Yehya

Published in

Critical care explorations. Volume 8. Issue 11. Pages e1520. Nov 01, 2026. Epub Nov 17, 2026.

Abstract

Neonates undergoing surgery for congenital heart disease (CHD) are at risk for poor postoperative outcomes after cardiopulmonary bypass (CPB), including death, prolonged ICU stay, and ICU readmission. Current prognostic models rely predominantly on nonmodifiable clinical factors.
To utilize machine learning methods to compare the predictive utility of preoperative blood biomarkers vs. clinical features alone for ICU-30, a validated composite outcome after neonatal CPB that includes postoperative 30-day morbidity and mortality.
Prospective observational single-center cohort study of consecutively enrolled neonates younger than 30 days undergoing CPB for CHD.
Plasma and clinical data were collected from consecutively enrolled neonates younger than 30 days immediately before CPB. Thirty-seven biomarkers were measured by individual or multiplex enzyme-linked immunosorbent assay and tested for association with ICU-30, defined as 1) mortality within 30 days of CPB, 2) ICU stay longer than 30 days, or 3) ICU readmission within 30 days. Predictive performance of extreme gradient boosting (XGBoost), least absolute shrinkage and selection operator, and random forest (RF) models was compared using the area under the receiver operating characteristic curve (AUROC). For XGBoost, the top 20 features were identified based on model importance (gain).
Biomarkers were available for 144 neonates. Most were male (51%), White (64%), and non-Hispanic (75%). Most operations were Society of Thoracic Surgeons-European Association for Cardiothoracic Surgery (STAT) category 3 (32%) or STAT category 5 (29%). ICU-30 occurred in 29 neonates (20%). Using combined clinical and biomarker data, XGBoost demonstrated moderate discrimination for ICU-30 (AUROC, 0.74), outperformed RF (AUROC, 0.72), and LASSO (AUROC, 0.70). Biomarkers alone performed better (AUROC, 0.72) than clinical data alone (AUROC, 0.67) with XGBoost. The top two features in the combined XGBoost model were neutrophil gelatinase-associated lipocalin (NGAL) and trefoil factor 3 (TFF3). Using Shapley additive explanation to assess both predictive impact and directionality, the most influential features were NGAL, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), and angiopoietin-2 (Ang-2).
Among neonates with CHD requiring CPB, multibiomarker models improved prediction of poor postoperative outcome compared with clinical variables alone. The most informative model features included markers of renal injury/perfusion and gastrointestinal epithelial injury (NGAL and TFF3), as well as vascular injury and inflammation (ADAMTS13 and Ang-2). These findings support further investigation of biomarker-informed risk stratification and may provide insight into pathophysiologic mechanisms underlying adverse postoperative outcomes.

PMID:
43043828
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement